Ampio Pharmaceuticals, Inc. AMPE
We take great care to ensure that the data presented and summarized in this overview for Ampio Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMPE
View allLatest Institutional Activity in AMPE
Top Purchases
Top Sells
About AMPE
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Insider Transactions at AMPE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2023
|
J Kevin Buchi Director |
BUY
Open market or private purchase
|
Direct |
21,858
+12.96%
|
$0
$0.29 P/Share
|
|
Jun 08
2023
|
J Kevin Buchi Director |
BUY
Open market or private purchase
|
Direct |
25,000
+16.67%
|
$0
$0.3 P/Share
|
|
May 24
2023
|
Michael A Martino CEO |
BUY
Open market or private purchase
|
Direct |
76,890
+50.0%
|
$0
$0.29 P/Share
|
|
May 16
2023
|
J Kevin Buchi Director |
BUY
Open market or private purchase
|
Direct |
32,534
+24.55%
|
$0
$0.27 P/Share
|
|
May 15
2023
|
J Kevin Buchi Director |
BUY
Open market or private purchase
|
Direct |
44,026
+39.49%
|
$0
$0.25 P/Share
|
|
May 12
2023
|
J Kevin Buchi Director |
BUY
Open market or private purchase
|
Direct |
23,440
+50.0%
|
$0
$0.24 P/Share
|
|
May 12
2023
|
David R Stevens Director |
BUY
Open market or private purchase
|
Direct |
45,000
+30.21%
|
$0
$0.22 P/Share
|
|
May 11
2023
|
David R Stevens Director |
BUY
Open market or private purchase
|
Direct |
50,000
+36.08%
|
$0
$0.22 P/Share
|
|
Jan 01
2022
|
Michael Macaluso |
SELL
Payment of exercise price or tax liability
|
Direct |
68,400
-2.54%
|
$0
$0.57 P/Share
|
|
Jan 01
2022
|
Holli Cherevka PRESIDENT AND COO |
SELL
Payment of exercise price or tax liability
|
Direct |
47,200
-10.31%
|
$0
$0.57 P/Share
|
|
Jan 01
2022
|
Dan Stokely CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,914
-6.84%
|
$0
$0.57 P/Share
|
|
Oct 27
2021
|
Michael Macaluso |
SELL
Payment of exercise price or tax liability
|
Direct |
43,470
-1.59%
|
$43,470
$1.64 P/Share
|
|
Oct 27
2021
|
Holli Cherevka PRESIDENT AND COO |
SELL
Payment of exercise price or tax liability
|
Direct |
41,980
-8.4%
|
$41,980
$1.64 P/Share
|
|
Oct 27
2021
|
Dan Stokely CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,127
-7.74%
|
$28,127
$1.64 P/Share
|
|
Oct 11
2021
|
Holli Cherevka PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+50.0%
|
-
|
|
Oct 11
2021
|
Dan Stokely CFO |
BUY
Grant, award, or other acquisition
|
Direct |
335,000
+47.97%
|
-
|
|
Oct 11
2021
|
Michael Macaluso |
BUY
Grant, award, or other acquisition
|
Direct |
950,000
+25.77%
|
-
|
|
Jun 25
2021
|
Dan Stokely CFO |
SELL
Open market or private sale
|
Direct |
22,500
-44.28%
|
$22,500
$1.79 P/Share
|
|
Jun 25
2021
|
Dan Stokely CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+30.69%
|
$0
$0.43 P/Share
|
|
May 21
2021
|
Philip H Coelho |
SELL
Open market or private sale
|
Direct |
6,737
-3.2%
|
$13,474
$2.0 P/Share
|